ELSEVIER

Clinica Chimica Acta 273 (1998) 213–214

Author index

Volume 273 (1998)

Adiloglu, A.K., Gurakur-Osborne, A., Prete, P.E., Standardized determination of apolipoprotein E phenotypes by simplified isoelectric focusing/immunoblotting in plasma and synovial fluid **273**, 99
Ala-Houhala, I.O., see Koskinen, L.K. **273**, 69
Asano, S., see Kikuchi, T. **273**, 1
Aubert, A.-C., see Voircl, P. **273**, 89

Babu, G.N., Bawari, M., Mathur, V.N., Kalita, J., Misra, U.K., Blood glutamate levels in patients with motor neuron disease **273**, 195
Baumann, P., see Voirol, P. **273**, 89
Bawari, M., see Babu, G.N. **273**, 195
Berland, Y.F., see Gallice, P.M. **273**, 149
Bing, X., see Qiaojia, H. **273**, 119
Blöck, T.M., see Lang, W. **273**, 43
Briand, G., see Fontaine, M. **273**, 161
Brunet, P.J., see Gallice, P.M. **273**, 149
Bydlowski, S.P., see Maeda, N.Y. **273**, 209

Calcote, C.B., see Roberts, W.L. **273**, 21
Carrère, J., Guy-Crotte, O., Figarella, C., Human pancreatic reg protein. Immunoenzymatic assay and molecular form in serum **273**, 185
Cook, C.B., see Roberts, W.L. **273**, 21
Crevat, A.D., see Gallice, P.M. **273**, 149

Degand, P., see Fontaine, M. **273**, 161
Divry, P., see Fontaine, M. **273**, 161

Figarella, C., see Carrère, J. **273**, 185
Fontaine, M., Briand, G., Largillière, C., Degand, P., Divry, P., Vianey-Saban, C., Mousson, B., Vamecq, J., Metabolic studies in a patient with severe carnitine palmitoyltransferase type II deficiency **273**, 161

Gallice, P.M., Kovacic, H.N., Brunet, P.J., Berland, Y.F., Crevat, A.D., A non ouabain-like inhibitor of the sodium pump in uremic plasma ultrafiltrates and urine from healthy subjects **273**, 149
Gordon, D.L., see Roberts, W.L. **273**, 21
Gurakur-Osborne, A., see Adiloglu, A.K. **273**, 99
Guy-Crotte, O., see Carrère, J. **273**, 185

Hänseler, E., see Otto, V.I. **273**, 131
Huang, C.-H., see Lan, F.-H. **273**, 13

Ishiguro, I., see Shinohara, R. **273**, 171

Jonzier-Perey, M., see Voirol, P. **273**, 89

Kalita, J., see Babu, G.N. **273**, 195
Kashiwabara, K., Nakamura, H., Kiguchi, T., Matsuoka, T., Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases **273**, 35
Kiguchi, T., see Kashiwabara, K. **273**, 35
Kikuchi, T., Kimata, S., Majima, K.-i., Asano, S., Determination of α-amylase using 4-*O*-β-D-galactopyranosylmaltotetraose (Gal-G4) as a substrate **273**, 1
Kimata, S., see Kikuchi, T. **273**, 1
Koivula, T.A., see Koskinen, L.K. **273**, 69
Koskinen, L.K., Ala-Houhala, I.O., Lahtela, J.T., Laippala, P.J., Koivula, T.A., Does uremia interfere with HbA_{1c} results in the FPLC method with Mono S cation exchanger? **273**, 69
Kovacic, H.N., see Gallice, P.M. **273**, 149

Lahtela, J.T., see Koskinen, L.K. **273**, 69
Laippala, P.J., see Koskinen, L.K. **273**, 69
Lan, F.-H., Tang, Y.-C., Huang, C.-H., Wu, Y.-S., Zhu, Z.-Y., Antibody-based spot test for NADH–

0009-8981/98/$19.00 Elsevier Science B.V. All rights reserved
PII S009-8981(98)00067-9

cytochrome b5 reductase activity for the laboratory diagnosis of congenital methemoglobinemia **273**, 13
Lang, W., Blöck, T.M., Zander, R., Solubility of NH_3 and apparent pK of NH_4^+ in human plasma, isotonic salt solutions and water at 37°C **273**, 43
Largillière, C., see Fontaine, M. **273**, 161
Li, L., see Qiaojia, H. **273**, 119
Lopes, A.A.B., see Maeda, N.Y. **273**, 209

Maeda, N.Y., Bydlowski, S.P., Lopes, A.A.B., Sialic acid content of von Willebrand factor subunit. A simple method for quantitative estimation **273**, 209
Majima, K.-i., see Kikuchi, T. **273**, 1
Manoharan, S., see Nagini, S. **273**, 95
Mathur, V.N., see Babu, G.N. **273**, 195
Matsuoka, T., see Kashiwabara, K. **273**, 35
Misra, U.K., see Babu, G.N. **273**, 195
Moore, M.L., see Roberts, W.L. **273**, 21
Moore, S., see Roberts, W.L. **273**, 21
Mousson, B., see Fontaine, M. **273**, 161

Nagini, S., Manoharan, S., Ramachandran, C.R., Lipid peroxidation and antioxidants in oral squamous cell carcinoma **273**, 95
Nakamura, H., see Kashiwabara, K. **273**, 35

Ohta, Y., see Shinohara, R. **273**, 171
O'Mullane, J., see Spillane, D.G. **273**, 81
Otto, V.I., Schär, B.K., Sulser, T., Hänseler, E., Specific determination of germ cell alkaline phosphatase for early diagnosis and monitoring of seminoma: performance and limitations of different analytical techniques **273**, 131

Pahwa, M.B., Seth, S., Seth, R.K., Lipid profile in various phases of menstrual cycle and its relationship with percentage plasma volume changes **273**, 201
Prasongwatana, V., see Sriboonlue, P. **273**, 59
Prete, P.E., see Adiloglu, A.K. **273**, 99

Qiaojia, H., Yuchai, T., Weiping, L., Shuxuan, Y., Xiaopeng, L., Bing, X., Yushui, W., Li, L., Zhongyong, Z., Qualitative bedside assay of increased human serum myoglobin by sandwich dot-immunogold filtration for the diagnosis of acute myocardial infarction **273**, 119

Ramachandran, C.R., see Nagini, S. **273**, 95
Roberts, W.L., Calcote, C.B., Cook, C.B., Gordon, D.L., Moore, M.L., Moore, S., Scheer, W.D., Snazelle, B.A., Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens **273**, 21
Rose, M.P., Follicle stimulating hormone. International standards and reference preparations for the calibration of immunoassays and bioassays **273**, 103

Schär, B.K., see Otto, V.I. **273**, 131
Scheer, W.D., see Roberts, W.L. **273**, 21
Seth, R.K., see Pahwa, M.B. **273**, 201
Seth, S., see Pahwa, M.B. **273**, 201
Shinohara, R., Ohta, Y., Yamauchi, M., Ishiguro, I., Improved fluorometric enzymatic sorbitol assay in human blood **273**, 171
Shuxuan, Yu., see Qiaojia, H. **273**, 119
Snazelle, B.A., see Roberts, W.L. **273**, 21
Spillane, D.G., O'Mullane, J., Development of an affinity-column-mediated enzyme-linked immunosorbent assay for ferritin **273**, 81
Sriboonlue, P., Suwantrai, S., Prasongwatana, V., An indirect method for urinary oxalate estimation **273**, 59
Sulser, T., see Otto, V.I. **273**, 131
Suwantrai, S., see Sriboonlue, P. **273**, 59

Tang, Y.-C., see Lan, F.-H. **273**, 13

Vamecq, J., see Fontaine, M. **273**, 161
Vianey-Saban, C., see Fontaine, M. **273**, 161
Voirol, P., Aubert, A.-C., Jonzier-Perey, M., Baumann, P., An automated procedure for the determination of protein concentration in subcellular fractions **273**, 89

Weiping, L., see Qiaojia, H. **273**, 119
Wu, Y.-S., see Lan, F.-H. **273**, 13

Xiaopeng, L., see Qiaojia, H. **273**, 119

Yamauchi, M., see Shinohara, R. **273**, 171
Yuchai, T., see Qiaojia, H. **273**, 119
Yushui, W., see Qiaojia, H. **273**, 119

Zander, R., see Lang, W. **273**, 43
Zhongyong, Z., see Qiaojia, H. **273**, 119
Zhu, Z.-Y., see Lan, F.-H. **273**, 13

ELSEVIER

Clinica Chimica Acta 273 (1998) 215–218

Subject index

Volume 273 (1998)

Acute myocardial infarction; Myoglobin; Dot-immunogold filtration assay; Enzyme-linked immunosorbent assay **273**, 119

Acylcarnitine; L-Carnitine; Carnitine palmitoyltransferase type II deficiency; Mass spectrometry **273**, 161

Alanine aminotransferase; Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Hemodialysis; Aspartate aminotransferase **273**, 35

Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Method bias; Microalbumin; Urinary albumin **273**, 21

Ammonia; Solubility; Apparent p*K*; Human plasma; Isotonic salt solutions; Water **273**, 43

α-Amylase; 4-*O*-β-D-Galactopyranosylmaltotetraose **273**, 1

Amyotrophic lateral sclerosis; Glutamate; Motor neuron disease; Excitotoxins; Progressive bulbar palsy **273**, 195

Analysis; Microsomes; Proteins; Automation **273**, 89

Analytical methods; Albumin/creatinine ratio; Diabetic nephropathy; Method bias; Microalbumin; Urinary albumin **273**, 21

Apparent p*K*; Ammonia; Solubility; Human plasma; Isotonic salt solutions; Water **273**, 43

Aspartate aminotransferase; Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Hemodialysis; Alanine aminotransferase **273**, 35

Automation; Microsomes; Proteins; Analysis **273**, 89

Bioassays; Follicle stimulating hormone (FSH); Immunoassays; Standards; Therapeutics **273**, 103

Carbohydrate structure; Sialic acid; von Willebrand factor; Glycoproteins **273**, 209

L-Carnitine; Acylcarnitine; Carnitine palmitoyltransferase type II deficiency; Mass spectrometry **273**, 161

Carnitine palmitoyltransferase type II deficiency; Acylcarnitine; L-Carnitine; Mass spectrometry **273**, 161

Chromatography, liquid; Hemoglobin A, glycated; Hemodialysis; *Diabetes mellitus* **273**, 69

Column regeneration; ELISA; Non-competitive; Enzyme amplification **273**, 81

Diabetes; Sorbitol; Sorbitol dehydrogenase; Human blood **273**, 171

Diabetes mellitus; Hemoglobin A, glycated; Hemodialysis; Chromatography, liquid **273**, 69

0009-8981/98/$19.00 Elsevier Science B.V. All rights reserved
PII S009-8981(98)00068-0

Diabetic nephropathy; Albumin/creatinine ratio; Analytical methods; Method bias; Microalbumin; Urinary albumin **273**, 21

Diagnostic specificity; Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Ion exchange chromatography; Immunoassay **273**, 131

Dot-immunogold filtration assay; Myoglobin; Acute myocardial infarction; Enzyme-linked immunosorbent assay **273**, 119

ELISA; Non-competitive; Column regeneration; Enzyme amplification **273**, 81

ELISA; Reg; Human; Pancreatic juice; Serum **273**, 185

Enzyme activity; NADH–cytochrome b5 reductase; Monoclonal antibody; Nitrocellulose; Recessive congenital methemoglobinemia **273**, 13

Enzyme amplification; ELISA; Non-competitive; Column regeneration **273**, 81

Enzyme-linked immunosorbent assay; Myoglobin; Acute myocardial infarction; Dot-immunogold filtration assay **273**, 119

Excitotoxins; Glutamate; Motor neuron disease; Amyotrophic lateral sclerosis; Progressive bulbar palsy **273**, 195

Follicle stimulating hormone (FSH); Immunoassays; Standards; Bioassays; Therapeutics **273**, 103

4-*O*-β-D-Galactopyranosylmaltotetraose; α-Amylase **273**, 1

Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Ion exchange chromatography; Immunoassay; Diagnostic specificity **273**, 131

Glutamate; Motor neuron disease; Excitotoxins; Amyotrophic lateral sclerosis; Progressive bulbar palsy **273**, 195

Glycoproteins; Sialic acid; von Willebrand factor; Carbohydrate structure **273**, 209

Hematocrit; Menstrual cycle; Lipid profile; Plasma volume; Hemoglobin **273**, 201

Hemodialysis; Hemoglobin A, glycated; Chromatography, liquid; *Diabetes mellitus* **273**, 69

Hemodialysis; Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Aspartate aminotransferase; Alanine aminotransferase **273**, 35

Hemoglobin A, glycated; Hemodialysis; Chromatography, liquid; *Diabetes mellitus* **273**, 69

Hemoglobin; Menstrual cycle; Lipid profile; Plasma volume; Hematocrit **273**, 201

Human blood; Sorbitol; Sorbitol dehydrogenase; Diabetes **273**, 171

Human plasma; Ammonia; Solubility; Apparent p*K*; Isotonic salt solutions; Water **273**, 43

Human; Reg; Pancreatic juice; Serum; ELISA **273**, 185

Immunoassays; Follicle stimulating hormone (FSH); Standards; Bioassays; Therapeutics **273**, 103

Immunoassay; Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Ion exchange chromatography; Diagnostic specificity **273**, 131

Ion exchange chromatography; Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Immunoassay; Diagnostic specificity **273**, 131

Isotonic salt solutions; Ammonia; Solubility; Apparent p*K*; Human plasma; Water **273**, 43

Lipid profile; Menstrual cycle; Plasma volume; Hematocrit; Hemoglobin **273**, 201

Liver cirrhosis; Tumor marker; Non-insulin-dependent diabetes mellitus; Hemodialysis; Aspartate aminotransferase; Alanine aminotransferase **273**, 35

Mass spectrometry; Acylcarnitine; L-Carnitine; Carnitine palmitoyltransferase type II deficiency **273**, 161

Menstrual cycle; Lipid profile; Plasma volume; Hematocrit; Hemoglobin **273**, 201

Method bias; Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Microalbumin; Urinary albumin **273**, 21

Microalbumin; Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Method bias; Urinary albumin **273**, 21

Microsomes; Proteins; Automation; Analysis **273**, 89

Monoclonal antibody; NADH–cytochrome b5 reductase; Enzyme activity; Nitrocellulose; Recessive congenital methemoglobinemia **273**, 13

Motor neuron disease; Glutamate; Excitotoxins; Amyotrophic lateral sclerosis; Progressive bulbar palsy **273**, 195

Myoglobin; Acute myocardial infarction; Dot-immunogold filtration assay; Enzyme-linked immunosorbent assay **273**, 119

NADH–cytochrome b5 reductase; Enzyme activity; Monoclonal antibody; Nitrocellulose; Recessive congenital methemoglobinemia **273**, 13

Nitrocellulose; NADH–cytochrome b5 reductase; Enzyme activity; Monoclonal antibody; Recessive congenital methemoglobinemia **273**, 13

Non-competitive; ELISA; Column regeneration; Enzyme amplification **273**, 81

Non-insulin-dependent diabetes mellitus; Tumor marker; Liver cirrhosis; Hemodialysis; Aspartate aminotransferase; Alanine aminotransferase **273**, 35

Ouabain; Sodium pump inhibitor; Uremia **273**, 149

Oxalate determination; Oxalate estimation **273**, 59

Oxalate estimation; Oxalate determination **273**, 59

Pancreatic juice; Reg; Human; Serum; ELISA **273**, 185

Plasma volume; Menstrual cycle; Lipid profile; Hematocrit; Hemoglobin **273**, 201

Progressive bulbar palsy; Glutamate; Motor neuron disease; Excitotoxins; Amyotrophic lateral sclerosis **273**, 195

Proteins; Microsomes; Automation; Analysis **273**, 89

Recessive congenital methemoglobinemia; NADH–cytochrome b5 reductase; Enzyme activity; Monoclonal antibody; Nitrocellulose **273**, 13

Reg; Human; Pancreatic juice; Serum; ELISA **273**, 185

Seminoma; Germ cell alkaline phosphatase; Two-dimensional electrophoresis; Ion exchange chromatography; Immunoassay; Diagnostic specificity **273**, 131

Serum; Reg; Human; Pancreatic juice; ELISA **273**, 185

Sialic acid; von Willebrand factor; Glycoproteins; Carbohydrate structure **273**, 209

Sodium pump inhibitor; Uremia; Ouabain **273**, 149

Solubility; Ammonia; Apparent p*K*; Human plasma; Isotonic salt solutions; Water **273**, 43

Sorbitol dehydrogenase; Sorbitol; Diabetes; Human blood **273**, 171

Sorbitol; Sorbitol dehydrogenase; Diabetes; Human blood **273**, 171

Standards; Follicle stimulating hormone (FSH); Immunoassays; Bioassays; Therapeutics **273**, 103

Therapeutics; Follicle stimulating hormone (FSH); Immunoassays; Standards; Bioassays **273**, 103

Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Hemodialysis; Aspartate aminotransferase; Alanine aminotransferase **273**, 35

Two-dimensional electrophoresis; Germ cell alkaline phosphatase; Seminoma; Ion exchange chromatography; Immunoassay; Diagnostic specificity **273**, 131

Uremia; Sodium pump inhibitor; Ouabain **273**, 149

Urinary albumin; Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Method bias; Microalbumin **273**, 21

Water; Ammonia; Solubility; Apparent p*K*; Human plasma; Isotonic salt solutions **273**, 43

von Willebrand factor; Sialic acid; Glycoproteins; Carbohydrate structure **273**, 209